Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that anti-TFRC antibody PPMX-T003 inhibits growth and metastasis in colorectal cancer, highlighting targeted iron transport blockade as a therapeutic strategy.
Advanced colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide, with distant metastasis and therapeutic resistance representing critical clinical hurdles. 1 Transferrin receptor (TFRC), a key iron transporter that is frequently overexpressed in tumors, plays a vital role in tumor progression and is correlated with poor prognosis. 2 While TFRC inhibition has been shown to suppress growth in various cancers, 3 its therapeutic effect on the CRC metastatic cascade remains unexplored. While the safety of PPMX-T003 (a clinical-stage, fully human anti-TFRC monoclonal antibody) has been confirmed in phase 1 trials for hematological conditions and a phase 1/2 trial is currently ongoing for aggressive natural killer-cell leukemia, 4 , 5 its efficacy against solid tumors remains unknown. To our knowledge, this is the first study to evaluate the efficacy of PPMX-T003 against CRC, providing novel preclinical evidence that direct TFRC inhibition effectively suppresses both primary tumor growth and metastatic spread.
No takes yet. Share an insight, caveat, or question.
Endo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: